The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

Agency commissioners voted unanimously on Tuesday to publish the report, which makes similar allegations against the ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...

CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...

FTC: ‘Big 3’ Pharmacy Benefit Managers Engaged in Price Gouging, PBMs, UnitedHealth OptumRx, CVS Caremark Rx, Express Scripts ...

The pressure against pharmacy benefit managers (PBMs) continues to build. On Tuesday, the Federal Trade Commission released ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...